Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 7/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920280 | 0.91 | PDE3B (0.42) | ALOX5APFFAR4MEN1KMT2APDE3B | |
| SCHEMBL6497506 | 0.91 | PDE3B (0.43) | ALOX5APMEN1KMT2APDE3BPDE3A | |
| SCHEMBL6497809 | 0.86 | MCL1 (0.41) | FFAR4MEN1KMT2AMCL1NPSR1 | |
| SCHEMBL6502820 | 0.84 | ALOX5AP (0.42) | ALOX5APMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL6488591 | 0.82 | ALOX5AP (0.44) | ALOX5APMCL1PLA2G2A | |
| SCHEMBL6920283 | 0.82 | FFAR4 (0.41) | FFAR4MEN1KMT2APDE3BPDE3A | |
| SCHEMBL6487805 | 0.80 | KDM4E (0.42) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL6490693 | 0.80 | MRGPRX4 (0.43) | ALOX5APNPSR1ALDH1A1GAA | |
| SCHEMBL6492273 | 0.78 | MCL1 (0.39) | FFAR4MEN1KMT2AMCL1NPSR1 | |
| SCHEMBL6501536 | 0.78 | PPARG (0.52) | ALOX5APFFAR4MEN1KMT2APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | ALOX5AP 4663/4885FFAR4 960/4885MEN1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.